ImPact BiotechPhase 3 ENLIGHTED study enrollment completion expected by first quarter of 2025TEL AVIV, Israel, Sept. 27, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced that the Phase 3 ENLIGHTED (ENdoluminal LIGHT ActivatED) trial evaluating Padeliporfin VTP in patients with low-grade UTUC has achieved 50% patient enrollment…
Read More…
Source: https://finance.yahoo.com/news/impact-biotech-announces-50-enrollment-120000012.html